

	Type	L #	Hits	Search Text	DBs
1	BRS	L1	61419	polypeptide	USPAT; US-PGPUB; EPO; JPO; DERWENT
2	BRS	L2	41051	(unique or repeated) with sequence	USPAT; US-PGPUB; EPO; JPO; DERWENT
3	BRS	L3	6925	11 and 12	USPAT; US-PGPUB; EPO; JPO; DERWENT
4	BRS	L4	1313	11 same 12	USPAT; US-PGPUB; EPO; JPO; DERWENT
5	BRS	L5	10864	(unique or repeated) adj3 sequence	USPAT; US-PGPUB; EPO; JPO; DERWENT
6	BRS	L6	3035	11 and 15	USPAT; US-PGPUB; EPO; JPO; DERWENT
7	BRS	L7	579	11 same 15	USPAT; US-PGPUB; EPO; JPO; DERWENT
8	BRS	L8	95	(unique or repeated) adj peptide adj sequence	USPAT; US-PGPUB; EPO; JPO; DERWENT
9	BRS	L9	33	18 and transport	USPAT; US-PGPUB; EPO; JPO; DERWENT
10	BRS	L10	49	(unique or repeated) with peptide with motif	USPAT; US-PGPUB; EPO; JPO; DERWENT
11	BRS	L11	548	penetrat\$3 with antibod\$3	USPAT; US-PGPUB; EPO; JPO; DERWENT
12	BRS	L12	47	111 and motif	USPAT; US-PGPUB; EPO; JPO; DERWENT
13	BRS	L13	0	(screening adj3 peptide adj library) same penetration	USPAT; US-PGPUB; EPO; JPO; DERWENT
14	BRS	L14	421	screening adj3 peptide adj library	USPAT; US-PGPUB; EPO; JPO; DERWENT
15	BRS	L15	114	114 same antibod\$3 same bind\$3	USPAT; US-PGPUB; EPO; JPO; DERWENT
16	BRS	L16	547	424/130.1.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT
17	BRS	L17	1	116 and 110	USPAT; US-PGPUB; EPO; JPO; DERWENT
18	BRS	L18	341	424/133.1.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT
19	BRS	L19	38	118 and motif	USPAT; US-PGPUB; EPO; JPO; DERWENT
20	BRS	L20	6	119 and penetrat\$3	USPAT; US-PGPUB; EPO; JPO; DERWENT
21	BRS	L21	136	424/134.1.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT
22	BRS	L22	32	121 and penetrat\$3	USPAT; US-PGPUB; EPO; JPO; DERWENT
23	BRS	L23	4	122 and motif	USPAT; US-PGPUB; EPO; JPO; DERWENT
24	BRS	L24	386	424/178.1.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT
25	BRS	L25	4	124 and penetrat\$3 and motif	USPAT; US-PGPUB; EPO; JPO; DERWENT
26	BRS	L26	1784	530/300.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT
27	BRS	L27	0	126 and (antibod\$3 same motif same penetrat\$3)	USPAT; US-PGPUB; EPO; JPO; DERWENT
28	BRS	L28	41	126 and (antibod\$3 same motif)	USPAT; US-PGPUB; EPO; JPO; DERWENT
29	BRS	L29	5940	530/350.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT
30	BRS	L30	138	129 and (antibod\$3 same motif)	USPAT; US-PGPUB; EPO; JPO; DERWENT

	Type	L #	Hits	Search Text	DBs
31	BRS	L31	11	130 and penetrat\$3	USPAT; US-PGPUB; EPO; JPO; DERWENT
32	BRS	L32	1182	530/387.1.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT
33	BRS	L33	160	132 and motif	USPAT; US-PGPUB; EPO; JPO; DERWENT
34	BRS	L34	154	133 and gene	USPAT; EPO; JPO; DERWENT
35	BRS	L35	45	133 and (gene adj therapy)	USPAT; EPO; JPO; DERWENT
36	BRS	L36	1423	514/44.ccls.	USPAT; EPO; JPO; DERWENT
37	BRS	L37	1009	136 and (antibod\$3)	USPAT; EPO; JPO; DERWENT
38	BRS	L38	268	137 and motif	USPAT; EPO; JPO; DERWENT
39	BRS	L39	76	138 and penetrat\$3	USPAT; EPO; JPO; DERWENT
40	BRS	L40	3155	435/4.ccls.	USPAT; EPO; JPO; DERWENT
41	BRS	L41	2	140 and (antibod\$3 same amino same acid same motif)	USPAT; EPO; JPO; DERWENT
42	BRS	L42	1	140 and (antibod\$3 same (amino adj acid adj motif))	USPAT; EPO; JPO; DERWENT
43	BRS	L43	22	ternynck.in.	USPAT; EPO; JPO; DERWENT
44	BRS	L44	61	avrameas.in.	USPAT; EPO; JPO; DERWENT
45	BRS	L45	42	144 and antibodies	USPAT; EPO; JPO; DERWENT
46	BRS	L46	1	145 and motif	USPAT; EPO; JPO; DERWENT
47	BRS	L47	22	buttin.in.	USPAT; EPO; JPO; DERWENT
48	BRS	L48	12	saron.in.	USPAT; EPO; JPO; DERWENT
49	BRS	L49	155	blondel.in.	USPAT; EPO; JPO; DERWENT
50	BRS	L50	5	149 and antibodies	USPAT; EPO; JPO; DERWENT
51	BRS	L51	219	couderc.in.	USPAT; EPO; JPO; DERWENT
52	BRS	L52	4	151 and antibodies	USPAT; EPO; JPO; DERWENT
53	BRS	L53	479	michelson.in.	USPAT; EPO; JPO; DERWENT
54	BRS	L54	0	153 and antobides	USPAT; EPO; JPO; DERWENT
55	BRS	L55	14	153 and antibodies	USPAT; EPO; JPO; DERWENT
56	BRS	L56	2	zipeto.in.	USPAT; EPO; JPO; DERWENT

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 11:43:36 ON 23 JUL 2001

L1 293 S (TERNYNCK, T?)/AU
L2 205 S L1 AND ANTIBODIES
L3 4 S L2 AND MOTIF
L4 1 DUP REM L3 (3 DUPLICATES REMOVED)
L5 15 S L2 AND PENETRAT###
L6 6 DUP REM L5 (9 DUPLICATES REMOVED)
L7 0 S (ABRAMEAS, A?)/AU
L8 35 S (AVRAMEAS, A?)/AU
L9 26 S L8 AND ANTIBODIES
L10 8 S L9 AND PENETRAT###
L11 3 DUP REM L10 (5 DUPLICATES REMOVED)
L12 975 S (AVRAMEAS, S?)/AU
L13 711 S L12 AND ANTIBOD###
L14 1 S L13 AND MOTIF
L15 16 S L13 AND PENETRAT###
L16 9 DUP REM L15 (7 DUPLICATES REMOVED)
L17 5 F SND 7
L18 326 S (BUTTIN, G?)/AU
L19 89 S L18 AND ANTIBOD###
L20 8 S L19 AND PENETRAT###
L21 3 DUP REM L20 (5 DUPLICATES REMOVED)
L22 128 S (SARON, M?)/AU
L23 32 S L22 AND ANTIBOD###
L24 17 DUP REM L23 (15 DUPLICATES REMOVED)
L25 482 S (BLONDEL, B?)/AU
L26 61 S L25 AND ANTIBOD###
L27 1 S L26 AND PENETRAT###
L28 1 S L26 AND TARGET####
L29 623 S (MICHELSON, S?)/AU
L30 74 S L29 AND ANTIBOD###
L31 2 S L30 AND PENETRAT###
L32 72 S (ZIPETO, D?)/AU
L33 7 S L32 AND ANTIBOD###
L34 4 DUP REM L33 (3 DUPLICATES REMOVED)
L35 344546 S POLYPEPTIDE
L36 930 S (UNIQUE OR REPEATED) (W) MOTIF
L37 61 S L35 (S) L36
L38 0 S L37 AND TRANSPORT
L39 0 S L37 AND PENETRAT###
L40 54 S L37 AND AMINO
L41 21 DUP REM L40 (33 DUPLICATES REMOVED)
L42 21 FOCUS L41 1-
L43 93 S L35 AND L36
L44 12 S L43 AND ANTIBOD###
L45 3 DUP REM L44 (9 DUPLICATES REMOVED)
L46 37350 S (UNIQUE OR REPEATED) (S) AMINO
L47 3881 S L35 (S) L46
L48 714 S L47 AND ANTIBOD###
L49 3 S L48 AND PENETRAT###
L50 37 S L48 AND TRANSPORT
L51 22 DUP REM L50 (15 DUPLICATES REMOVED)
L52 1185 S L47 AND BIND###
L53 2 S L52 AND HYPERVARIABLE
L54 35 S L52 AND HEAVY
L55 17 DUP REM L54 (18 DUPLICATES REMOVED)
L56 1 S L55 AND CDR#
L57 1828990 S ANTIBOD###
L58 8163 S L57 AND PENETRAT###

L59 5603 S L58 AND CELL
L60 5 S L58 AND INTERNALIZE
L61 3 DUP REM L60 (2 DUPLICATES REMOVED)
L62 652 S L58 AND TRANSPORT